Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on the results of the multi-center prospective Phase II study of Dose-Adjusted EPOCH-R for Burkitt Lymphoma.
We use necessary cookies to make this site work. Analytics, preference, and marketing cookies are used only if you choose to allow them. You can change your choice at any time. For more information view our Cookie Policy.